Navigation Links
AMP releases statement on diagnostics in drug labels
Date:5/16/2011

White Oak, MDMay 16, 2011 Today, the Association for Molecular Pathology (AMP) released its new position statement on the appropriate manner to reference diagnostic tests in drug labels. The association also met with officials from the United States Food and Drug Administration that participate in the effort to draft guidance documents for co-developed products and companion diagnostics to inform them of its new position statement.

With advances in genomic medicine, providers can use targeted therapy to tailor dosing, improve drug response, and to avoid adverse events. Pharmaceutical manufacturers control the label's content and can choose to describe a laboratory test by its molecular description or by its brand name. The latter limits pathologists from choosing the test that best suits the needs of their patients, physicians and laboratory environment. And rather than consulting with the molecular pathologist to consider all relevant information from the patient's medical history, together with the most effective laboratory testing strategy at the least cost, treating physicians such as oncologists may reflexively order the test listed in the labeling. Therefore, referencing diagnostic tests by their brand names in drug labeling may create a situation where patients are not receiving optimal care.

"When the FDA approves a label that includes a brand name of a diagnostic kit, the medical community often views this as a tacit endorsement of that one company's test," explained AMP Professional Relations Committee Chair Dr. Elaine Lyon, "Indeed, diagnostic companies' marketing strategies might exploit this view."

Because healthcare providers may request testing using the test identified in the drug labeling, and payers may only reimburse if that specific test is used, laboratories will be put in the challenging position of having to purchase and verify multiple test kits for the same analyte. In addition, if a diagnostic company was to sell its test exclusively to one laboratory, all specimens would have to be shipped to that laboratory for testing even if the source laboratory has access to a different FDA approved or cleared test for the same analyte. Dr. Lyon expressed AMP's concern, "this would drastically increase healthcare costs and over-complicate the laboratory environment. And our greatest concern is that it could result in restricting the patient's access to one specific test, which may create additional burdens to the patient including the collection of subsequent samples, increased out-of-pocket costs, and delayed treatment."

AMP hopes that this new position statement will encourage pharmaceutical companies to reference diagnostic tests based on its molecular description and the FDA to work with industry to reinforce the appropriate labeling of its products.

AMP's specific recommendations include:

  • To promote patient safety and high quality care, AMP recommends that FDA specify that diagnostics be described by the biological description of the gene or mutation in drug labeling and that identification of recommended diagnostic testing not be by brand name. Essential performance characteristics (e.g. limit of detection) can be specified. Standardized HUGO nomenclature should be used.

  • AMP notes that The Clinical Laboratory Standards Institute (CLSI) avoids identifying products by brand name in their Guidelines.

  • Identification of diagnostic tests by brand name in drug labeling is only appropriate in the description of relevant clinical studies; AMP recommends that in the remainder of the label, pharmaceutical manufacturers reference the biological description.


'/>"/>

Contact: Mary Williams
mwilliams@amp.org
301-634-7921
Association for Molecular Pathology
Source:Eurekalert

Related medicine news :

1. IADR/AADR Journal of Dental Research releases studies on oral health inequalities in older people
2. TBI Therapy and Nutrition: IOM report releases April 20
3. Physics story tops EurekAlert!s 2010 list of most-visited releases
4. California Health Interview Survey releases newest data on state residents health
5. IADR/AADR Journal of Dental Research releases large studies on osteonecrosis of the jaw
6. National committee releases findings on transforming and improving the nursing profession
7. Womens health research: IOM releases progress report Sept. 23
8. Research!America releases vaccines fact sheet
9. MedPage Today Releases Free App for Android Phones
10. Bellaboo Releases One Girl At A Time Documentary
11. Purity Products Releases Alpha 3C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... NY (PRWEB) , ... October 13, 2017 , ... Ellevate ... people in business to advocate for action towards gender equality at their inaugural Summit ... from around the globe, and reached a social audience of over 3 million. To ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... and Agile Software Development, has been awarded a contract by the Center for ... Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in a ...
(Date:10/12/2017)... San Francisco, CA (PRWEB) , ... October 12, ... ... and Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus ... sleep apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) ... FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s ... Morris F. Collen, a pioneer in the field of medical informatics, this prestigious award ...
(Date:10/12/2017)... Malvern, PA (PRWEB) , ... October 12, 2017 , ... ... is the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best ... New York City on October 11, 2017. , The annual award competition recognizes editorial ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ® ... fulfilling the promise of precision medicine, today announced that ... Caris, Precision Oncology Alliance™ (POA) as its 17 th ... the St. Jude Crosson Cancer Institute will help develop ... use of tumor profiling, making cancer treatment more precise ...
(Date:10/10/2017)... Oct. 10, 2017  NDS received FDA 510(k) clearance in May ... battery-powered display stand specifically designed for endoscopy environments. An innovative secondary ... a clinical solution to support the improvement of patient outcomes, procedural ... ... ...
(Date:10/5/2017)... , Oct. 5, 2017  In response ... of Oral and Maxillofacial Surgeons (AAOMS) released prescribing ... – to be used as a first-line therapy ... Recognizing the ... AAOMS White Paper "Opioid Prescribing: Acute and Postoperative ...
Breaking Medicine Technology: